Maximizing survival in metastatic castrate-resistant prostate cancer: A clinical viewpoint

Expert Review of Anticancer Therapy

Volumn 13, Issue 1, 2013, Pages 89-99

  Birtle, Alison ^a  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

abiraterone; cabazitaxel; disease progression; docetaxel; metastatic castrate resistant prostate cancer; survival; treatment sequencing

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; BICALUTAMIDE; CABAZITAXEL; CABOZANTINIB; DENOSUMAB; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; ENZALUTAMIDE; LOPERAMIDE; MITOXANTRONE; NARCOTIC ANALGESIC AGENT; PLACEBO; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SIPULEUCEL T; SUNITINIB; ZOLEDRONIC ACID;

ADVANCED CANCER; ASTHENIA; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; HYPOKALEMIA; LICENCE; MEDICAL DECISION MAKING; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; REVIEW; SIDE EFFECT; SURVIVAL TIME; SYSTEMIC THERAPY; THRUSH;

ANDROSTENOLS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 84871531559     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.160     Document Type: Review

References (38)

1. The British Association of Urological Surgeons: Section of Oncology. BAUS Cancer Registry: Analyses of Minimum Data Set for Urological Cancers January 1st-31st December 2008. BAUS, London, UK (2009).
2. National Institute for Health and Clinical Excellence. Docetaxel for the Treatment of Hormone-Refractory Metastatic Prostate Cancer. NICE, London, UK (2009).
3. Anderson J. The need for improved therapeutic strategies for patients with metastatic hormone-refractory prostate cancer. Eur. Urol. Suppl. 5, 811-816 (2006).
4. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14(6), 1756-1764 (1996).
5. Tannock IF, de Wit R, Berry WR et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004).
6. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26(2), 242-245 (2008).
7. Zhang B, Suer S, Livak F et al. Telomere and microtubule targeting in treatmentsensitive and treatment-resistant human prostate cancer cells. Mol. Pharmacol. 82(2), 310-321 (2012).
8. Bissery MC. Preclinical evaluation of new taxoids. Curr. Pharm. Des. 7(13), 1251-1257 (2001).
9. Cisternino S, Bourasset F, Archimbaud Y, Sémiond D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br. J. Pharmacol. 138(7), 1367-1375 (2003).
10. Mita AC, Denis LJ, Rowinsky EK et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 15(2), 723-730 (2009).
11. de Bono JS, Oudard S, Ozguroglu M et al.; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147-1154 (2010).
12. Lathia N, Isogai PK, de Angelis C et al. Factors influencing patient preferences for outpatient treatment of febrile neutropenia. Presented at: 2011 ASCO Annual Meeting. Chicago, IL, USA, 3-7 June 2011.
13. Lydon A. Cabazitaxel side effects: prevention and management. Br. J. Med. Surg. Urol. 4S, S21-S27 (2011).
14. Sartor AO, Tangen CM, Hussain MH et al.; Southwest Oncology Group. Antiandrogen withdrawal in castraterefractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112(11), 2393-2400 (2008).
15. Bahl A, Masson S, Malik Z et al. Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279). Presented at: 2012 ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 2-4 February 2012.
16. de Bono JS, Logothetis CJ, Molina A et al.; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011).
17. Scher HI, Heller G, Molina A et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled Phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. Presented at: 2011 ASCO Annual Meeting. Chicago, IL, USA, 3-7 June 2011.
18. Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol. Oncol. 24(1), 4-12 (2006).
19. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a Phase 3, randomised, placebo-controlled trial. Lancet 379(9810), 39-46 (2012).
20. Scher HI, Fizazi K, Saad F et al. Effect of MDV3100, an androgen receptor signalling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the Phase III AFFIRM study. Presented at: 2012 ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 2-4 February 2012.
21. de Bono JS, Fizazi K, Saad F et al. Primary, secondary, and quality-of-life endpoint results from the Phase III AFFIRM study of MDV3100, an androgen receptor signalling inhibitor. Presented at: 2012 ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 2-4 February 2012.
22. Parker C, Heinrich D, O'Sullican JM et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a Phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. Presented at: 2012 ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 2-4 February 2012.
23. Parker C, Nilsson S, Heinrich D et al. Updated analysis of the Phase III, double-blind, randomized, multinational study of radium-223 chloride in castrationresistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). Presented at: 2012 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2012.
24. Hussain M, Smith MR, Sweeney PG et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a Phase II randomized discontinuation trial. Presented at: 2011 ASCO Annual Meeting. Chicago, IL, USA, 3-7 June 2011.
25. Kantoff PW, Higano CS, Shore ND et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
26. Thuret R, Massard C, Gross-Goupil M et al. The postchemotherapy PSA surge syndrome. Ann. Oncol. 19(7), 1308-1311 (2008).
27. National Institute for Health and Clinical Excellence. Single Technology Appraisal (STA): Abiraterone Acetate (Zytiga®) for the Treatment of Metastatic Castration Resistant Prostate Cancer Following Previous Cytotoxic Therapy. NICE, London, UK (2012).
28. Chi KN, Scher HI, Molina A et al. Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COUAA-301, a Phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2012 ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 2-4 February 2012.
29. National Chemotherapy Advisory Group. Chemotherapy Services in England: Ensuring Quality and Safety. National Chemotherapy Advisory Group, London, UK (2009).
30. National Confidential Enquiry into Patient Outcome and Death. For Better, for Worse? National Confidential Enquiry into Patient Outcome and Death, London, UK (2008).
31. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 52(4), e56-e93 (2011).
32. Dorff TB, Quinn DI. Cabazitaxel in prostate cancer: stretching a string. Lancet 376(9747), 1119-1120 (2010).
33. Hardwick J. Cabazitaxel for prostate cancer: patient preparation and ongoing care. Br. J. Nurs. 21(9), S13-S17 (2012).
34. Cornford P. Evolution of docetaxel-based therapy for metastatic castrate-resistant prostate cancer. Br. J. Med. Surg. Urol. 3(6), 225-230 (2010).
35. Malik ZI, Montazeri AH, Wong H et al. Post docetaxel treatment for castrationresistant prostate cancer (CRPC): does sequencing matter? Presented at: 2012 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2012.
36. Han K, Lee Y, Choi Y, Yang S, Hong S. Serum alkaline phosphatase as a supplementary biomarker for differentiating PSA surge from progression in patients with androgenindependent prostate cancer receiving systemic chemotherapy. Presented at: 2010 ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010.
37. Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Corey E. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer 10, 244 (2010).
38. Ryan CJ, Smith MR, de Bono JS et al. Interim analysis (IA) results of COUAA-302, a randomized, Phase III study of abiraterone acetate (AA) in chemotherapynaive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2012 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2012.